期刊文献+

不同剂量非布司他治疗高尿酸血症伴痛风的效果观察 被引量:5

Observation on the effect of different doses of febuxostat on hyperuricemia with gout
在线阅读 下载PDF
导出
摘要 目的探讨不同剂量非布司他治疗高尿酸血症伴痛风的效果。方法分析我院2016年2月~2019年3月收治的98例高尿酸血症伴痛风患者临床资料,依据随机纸片法进行分组,治疗Ⅰ组(48例)和治疗Ⅱ组(50例)。观察两组患者治疗前后尿酸水平、尿酸达标率情况,观察两组患者临床疗效和不良反应发生情况。结果两组患者治疗前尿酸水平比较,差异无统计学意义(P>0.05),两组患者治疗后尿酸水平均低于治疗前,尿酸达标率高于治疗前,治疗Ⅱ组患者治疗后尿酸水平均低于治疗Ⅰ组,尿酸达标率高于治疗Ⅰ组,治疗Ⅱ组患者治疗总有效率高于治疗Ⅰ组,差异均有统计学意义(P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论80mg剂量非布司他治疗高尿酸血症伴痛风患者,尿酸水平降低更明显,疗效良好,不良反应少。 Objective To investigate the effect of different doses of febuxostat on hyperuricemia with gout.Methods The clinical data of 98 patients with hyperuricemia and gout admitted to our hospital from February 2016 to March 2019 were analyzed.The patients were randomly divided into group I(n=48)and group II(n=50)according to the random paper method.Uric acid level and uric acid standard-reaching rate were observed before and after treatment in the two groups.The clinical efficacy and incidence of adverse reactions of the two groups were observed.Results Comparison of uric acid levels before treatment between the two groups showed no statistically significant difference(P>0.05).In both groups,the uric acid level after treatment was lower than that before treatment,and the uric acid standard-reaching rate was higher than that before treatment.After treatment,the uric acid level in group II was lower than that in group I,and the uric acid standard-reaching rate was higher than that in group I.The total effective rate in group II was higher than that in group I.The differences were statistically significant(P<0.05).Comparison of total incidence of adverse reactions between the two groups showed no statistically significant difference(P>0.05).Conclusion In patients with hyperuricemia and gout treated with 80mg of febuxostat,the uric acid level can be significantly reduced,with good efficacy and fewer adverse reactions.
作者 汤一榕 宋一帆 王修康 黄开敏 陈琦 陈仁利 TANG Yirong;SONG Yifan;WANG Xiukang;HUANG Kaimin;CHEN Qi;CHEN Renli(Department of General Practitioner,Ningde Hospital Affiliated to Ningde Normal University,Fujian,Ningde 352100,China)
出处 《中国医药科学》 2020年第18期79-81,127,共4页 China Medicine And Pharmacy
关键词 不同剂量 非布司他 高尿酸血症 痛风 Different doses Febuxostat Hyperuricemia Gout
  • 相关文献

参考文献16

二级参考文献105

  • 1Park SH,Shin WY, Lee EY, et al. The impact of hyperurice-mia on in-hospital mortality and incidence of acute kidney inju-ry in patients undergoing percutaneous coronary intervention[Jl. Circulation Journal, 2011,75(3): 692-697.
  • 2Kansui Y,Ohtsubo T,Goto K, et al. Association of serum u-ric acid with blood pressure in Japanese men: Cross-sectionalstudy in work-site group [J]. Circulation Journal f 2011, 75(12): 2827-2832.
  • 3Fagugli RM, Gentile G,Ferrara G, et al. Acute renal and he-patic failure associated with allopurinol treatment [ J]. ClinNephrol, 2008,70(6): 523*526.
  • 4Halevy S,Ghislain PD, Mockenhaupt M,et al. Allopurinol isthe most common cause of Stevens-Johnson syndrome and tox-ic epidermal necrolysis in Europe and Israel[J]. Journal of theAmerican Academy of Dermatology? 2008,58(1): 25-32.
  • 5Becker MA, Schumacher HR, Wortmann RL, et al. Febux-ostat compared with allopurinol in patients with hyperuricemiaand gout[J]. N Engl,2005, 353(353): 2450-2461.
  • 6Akira Sezai, Masayoshi Soma, Kin-ichi Nakata, et al. Com-parison of Febuxostat and Allopurinol for Hyperuricemia in(8): 2043-2049.
  • 7Matsumoto K, Okamoto K. Ashizawa N, et al. FYX-051 : Anovel and potent hybrid-type inhibitor of xanthine oxidoreduc-tase[J]. Journal of Pharmacology Experimental Therapeu-tics, 2010, 336(1): 95-103.
  • 8Burns CM, Wortmann RL. Gout therapeutics: New drugs foran old disease[J]. Lancet, 2011, 377(9760) : 165-t77.
  • 9Tatuo H, Iwao O. A repeated oral administration study of fe-buxostat (TMX-67), a non-purine-selective inhibitor of xan-thine oxidase in patients with impaired renal function in Japan:pharmacokinetic and pharmacodynamic study [J]. Journal ofClinical Rheumatology Practical Reports on Rheumatic &-Musculoskeletal Diseases,2011,17(4 Suppl 2) : 27-34.
  • 10European Medicines Agency. AdenuricTM ( febuxostat) : EP-AR-product information[EB/OL], [2011-01-22].

共引文献278

同被引文献45

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部